Form HealthvsRo Body

Form Health is a telehealth obesity clinic, not a drug itself. After an online intake, you are matched with a care team led by an ABOM-certified obesity-medicine physician (or advanced practice provider) plus a registered dietitian. They review your history and, when medically appropriate, prescribe FDA-approved anti-obesity medications such as Wegovy (semaglutide), Zepbound (tirzepatide), Saxenda (liraglutide), or Contrave. Most of these are GLP-1-based drugs that mimic gut hormones to slow stomach emptying, reduce appetite, and curb cravings (tirzepatide also acts on the GIP receptor). Care is delivered through video visits, unlimited messaging, and an app for weight and food tracking, combining medication with nutrition and behavior change.

Ro Body itself is a service layer, not a drug. You complete an online intake, a licensed clinician reviews your history, and, if appropriate, prescribes an FDA-approved GLP-1 (or dual GLP-1/GIP) medication such as Wegovy or Ozempic (semaglutide) or Zepbound (tirzepatide). These medicines mimic gut hormones that signal fullness to the brain, slow stomach emptying, and reduce appetite and food cravings, so most people eat less and lose weight. Ro layers on monthly provider check-ins, unlimited messaging, registered-nurse coaching, a behavior-change curriculum, dose-titration support, and an insurance concierge that submits prior authorizations to help you pursue coverage.

Form Health reports an average of 16% body-weight loss at 18 months across its patients (with and without medication), but this is the company's own internal program data, not an independently published, peer-reviewed clinical trial, so treat it as a marketing claim rather than proof. The medications Form prescribes do have strong trial evidence. In the STEP-1 trial (NEJM, 2021), adults on weekly semaglutide 2.4 mg (Wegovy) lost an average of about 14.9% of body weight at 68 weeks versus 2.4% on placebo. In SURMOUNT-1 (NEJM, 2022), tirzepatide (Zepbound) produced average losses of roughly 15% to 21% over 72 weeks depending on dose (about 15.0% at 5 mg up to 20.9% at 15 mg in the primary analysis, and higher, up to about 22.5%, among adherent participants). Real-world telehealth outcomes are often somewhat lower than trial figures because of drug discontinuation and adherence.

Ro cites average weight loss of roughly 15% of body weight over a year, a figure that tracks the medications' pivotal trials rather than a separate Ro study. In the STEP 1 trial (Wilding et al., NEJM 2021; n=1,961), once-weekly semaglutide 2.4 mg (Wegovy) produced a mean 14.9% weight loss at 68 weeks versus 2.4% for placebo, with 86.4% of participants losing at least 5%. For tirzepatide (Zepbound), the SURMOUNT-1 trial (Jastreboff et al., NEJM 2022; n=2,539) showed mean losses of 16.0%, 21.4%, and 22.5% at the 5, 10, and 15 mg doses versus 2.4% for placebo over 72 weeks. These results reflect the medication combined with lifestyle change, and weight tends to return after stopping. Individual results vary.

Side effects come from the prescribed medication, not the service itself. The most common with GLP-1 drugs (Wegovy, Zepbound, Saxenda) are gastrointestinal: nausea, diarrhea, vomiting, constipation, and abdominal discomfort, usually mild-to-moderate and worst during dose escalation. Contrave can cause nausea, headache, constipation, insomnia, and raised blood pressure. Serious but uncommon risks include acute pancreatitis, gallbladder disease, and kidney injury from dehydration. GLP-1 drugs carry an FDA boxed warning for thyroid C-cell tumors seen in rodents and are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Seek prompt medical care for severe, persistent abdominal pain.

The most common side effects come from the GLP-1 medication, not the platform: nausea, vomiting, diarrhea, constipation, stomach pain, indigestion, gas, fatigue, and headache. These are usually mild to moderate, worst when starting or raising the dose, and tend to ease over time. Serious but less common risks include pancreatitis (severe, persistent abdominal pain), gallbladder problems and gallstones, kidney problems from dehydration, low blood sugar (especially if combined with insulin or a sulfonylurea), and, rarely, serious allergic reactions. Wegovy, Ozempic, and Zepbound carry an FDA boxed warning for thyroid C-cell tumors seen in rodents; whether this risk applies to humans is unknown. Stop the medication and seek care for severe stomach pain.

As of 2026, Form Health's self-pay membership is about $299/month, which is HSA/FSA-eligible and covers physician and dietitian visits, messaging, and the app, but not medications or lab work. GLP-1 drugs can cost roughly $500 to $1,300 or more per month at cash price (manufacturer savings programs and lower-cost direct-pay vials for Wegovy and Zepbound can reduce this). Alternatively, Form can bill visits, labs, and medications through most major private insurance plans, in which case you pay only copays and deductibles, which can dramatically lower total cost. Medicare is more limited: by federal law it does not cover a drug prescribed solely for weight loss, so a GLP-1 is generally covered only when prescribed for a separate approved indication such as type 2 diabetes or cardiovascular risk reduction. Coverage varies widely by plan, so verify your specific benefits in writing before starting.

As of 2026, Ro Body membership is about $45 the first month and roughly $145/month after, and is lower if you prepay annually (Ro's own site has listed figures closer to $39 first month and $149/month month-to-month, so confirm the current price at checkout). The membership fee is generally not covered by insurance, though HSA/FSA funds may apply. Medication is billed separately and is the bigger variable. If your insurance covers brand Wegovy or Zepbound, savings cards can bring your out-of-pocket cost down to as little as $0 to $25/month. Without coverage, cash-pay options through programs like NovoCare and LillyDirect have run roughly $300 to $500/month for self-pay vials or pens in 2026 (with introductory pricing as low as ~$199 for early Wegovy fills), and Ro advertises additional prepay savings. Confirm your specific drug, dose, and coverage before committing, because total out-of-pocket varies widely.

Form Health is for US adults 18 and older with a BMI of 30 or higher, or 27 or higher with a weight-related condition such as type 2 diabetes, high blood pressure, or high cholesterol. You must have a primary care provider and have seen them within the past 12 months, since Form coordinates with (rather than replaces) your PCP. It is not appropriate for people seeking treatment for an eating disorder, those who are pregnant or breastfeeding, or anyone with contraindications to the prescribed medication. GLP-1 drugs like Wegovy and Zepbound are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Always disclose your full medical history; the prescribing physician makes the final call.

Generally for US adults with obesity (BMI 30+) or overweight (BMI 27+) plus a weight-related condition such as type 2 diabetes, high blood pressure, or high cholesterol, who want medication-supported weight loss. Not appropriate for, and the underlying GLP-1 drugs are contraindicated in, anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or with a prior serious hypersensitivity reaction to the drug. Not for use in pregnancy or breastfeeding, and clinicians use caution with a history of pancreatitis, gallbladder disease, or severe gastrointestinal disorders. A clinician makes the final call, and some applicants are found ineligible.